Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2015, Article ID 106954, 7 pages
http://dx.doi.org/10.1155/2015/106954
Research Article

Relationships between Serum Levels of Atazanavir and Renal Toxicity or Lithiasis

1Infectious Disease Service, Son Espases Hospital, Carretera de Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain
2Multidisciplinary Group for Infectious Disease Service, Institute of Health Sciences Research, IdISPa, Health Research Foundation Ramón Llull (FISIB), Son Espases Hospital, Carretera de Valldemossa 79, Building “S”, 1st Floor, Palma de Mallorca, 07010 Illes Balears, Spain
3Clinical Analysis Service, Son Espases Hospital, Carretera de Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain
4Pharmacy Service, Son Espases Hospital, Carretera de Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain
5Laboratory of Renal Lithiasis Research (IUNICS-IDISPa), Universitat de les Illes Balears, Carretera de Valldemossa, km 7.5, Palma de Mallorca, 07010 Illes Balears, Spain
6Clinical Trials Unit, Son Espases Hospital, Carretera Valldemossa 79, Palma de Mallorca, 07010 Illes Balears, Spain

Received 8 January 2015; Accepted 20 April 2015

Academic Editor: Glenda Gray

Copyright © 2015 C. I. Marinescu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. T. N. Vo, B. Ledergerber, O. Keiser et al., “Durability and outcome of initial antiretroviral treatments received during 2000-2005 by patients in the Swiss HIV cohort study,” Journal of Infectious Diseases, vol. 197, no. 12, pp. 1685–1694, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Squires, A. Lazzarin, J. M. Gatell et al., “Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 36, no. 5, pp. 1011–1019, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. J.-M. Molina, J. Andrade-Villanueva, J. Echevarria et al., “Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study,” Journal of Acquired Immune Deficiency Syndromes, vol. 53, no. 3, pp. 323–332, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. Reyataz (Atazanavir Sulfate): Full Prescription Information, Bristol-Myers Squibb, Princeton, NJ, USA, 2012.
  5. Y. Hamada, T. Nishijima, K. Watanabe et al., “High incidence of renal stones among hiv-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy,” Clinical Infectious Diseases, vol. 55, no. 9, pp. 1262–1269, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Rockwood, S. Mandalia, M. Bower, B. Gazzard, and M. Nelson, “Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir,” AIDS, vol. 25, no. 13, pp. 1671–1673, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. F.-A. Dauchy, S. Lawson-Ayayi, R. de la Faille et al., “Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy,” Kidney International, vol. 80, no. 3, pp. 302–309, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. C. Kalayjian, B. Lau, R. N. Mechekano et al., “Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care,” AIDS, vol. 26, no. 15, pp. 1907–1915, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Mocroft, O. Kirk, P. Reiss et al., “EuroSIDA Study Group.: estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients,” AIDS, vol. 24, no. 11, pp. 1667–1678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Fabbiani, L. Bracciale, M. Doino et al., “Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients,” Journal of Infection, vol. 62, no. 4, pp. 319–321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Giambenedetto, M. Fabbiani, M. Colafigli et al., “Safety and feasibility of treatment simplification to atazanavir/ritonavir+lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors+atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study),” Journal of Antimicrobial Chemotherapy, vol. 68, no. 6, pp. 1364–1372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Nishijima, Y. Hamada, K. Watanabe et al., “Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients,” PLoS ONE, vol. 8, no. 10, Article ID e77268, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. H. Teichman, “Acute renal colic from ureteral calculus,” The New England Journal of Medicine, vol. 350, no. 7, pp. 684–693, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Trinchieri, “Epidemiological trends in urolithiasis: impact on our health care systems,” Urological Research, vol. 34, no. 2, pp. 151–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. O. W. Moe, “Kidney stones: pathophysiology and medical management,” The Lancet, vol. 367, no. 9507, pp. 333–344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. V. de Lastours, E. F. R. de Silva, M. Daudon et al., “High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 8, Article ID dkt125, pp. 1850–1856, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Cousigou, M. Daudon, J. L. Maynard et al., “Urolithiasis in HIV-positive patients treated with atazanavir,” Clinical Infectious Diseases, vol. 45, no. 8, pp. e105–e108, 2007. View at Publisher · View at Google Scholar
  18. F. Grases, R. Garca-Gonzlez, E. Redondo et al., “Effects of escin on indinavir crystallization time in the urine of patients with HIV-I infection: a multicenter, randomized, open-label, controlled, four-period crossover trial,” Clinical Therapeutics, vol. 26, no. 12, pp. 2045–2055, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Rusconi, R. Gagliardini, S. Falvella et al., “Atazanavir (ATV) trough levels and CYP3A polymorphisms in HIV-1-infected patients,” in Proceedings of the 14th European AIDS Conference (EACS '13), PE10/1, Brussels, Belgium, October 2013.
  20. A. di Biagio, R. Prinapori, D. Giannarelli et al., “Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 1, pp. 200–205, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Sidawi, M. Uriol, A. Payeras, A. A. Campins, F. Fanjul, and M. Riera, “Enfermedad renal crónica en pacientes con infección VIH: estudio de prevalencia, evolución temporal y factores asociados,” in XVII Congreso Sociedad Española de Enfermedades Infecciosas y Microbiologia Clínica, Zaragoza, Spain, May 2013.
  22. P. Flandre, P. Pugliese, L. Cuzin et al., “Risk Factors of chronic kidney disease in HIV-infected patients,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 7, pp. 1700–1707, 2011. View at Publisher · View at Google Scholar · View at Scopus